Feasibility and Efficacy of Subcutaneous Amifostine Therapy in Patients With Head and Neck Cancer Treated With Curative Accelerated Concomitant-Boost Radiation Therapy

Ozşahin, Mahmut; Betz, Michael; Matzinger, Oscar; Bron, Luc; Lüthi, François; Pelletier, Philippe; Azria, D.; Mirimanoff, R.O.; Zouhair, Abderrahim

doi:10.1001/archotol.132.2.141

Cited by 24 publications

(15 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subcutaneous administration has been tested for the prevention of oral mucositis in head and neck cancer patients, who received radiotherapy or chemoradiotherapy. A total of six articles were reviewed [18,31,[41][42][43][44].…”

Section: Subcutaneous Administrationmentioning

confidence: 99%

“…Four articles were reviewed [31,41,43,44]. The rate of oral mucositis was not improved with amifostine in one randomized but neither blinded nor placebo-controlled study [31].…”

Section: Chemoradiotherapy: Preventionmentioning

confidence: 99%

“…The rate of oral mucositis was not improved with amifostine in one randomized but neither blinded nor placebo-controlled study [31]. The other three studies tested the feasibility of the use of subcutaneous amifostine [41,43,44]. One of them combined 26 patients who received chemoradiotherapy with seven patients, who received radiotherapy alone [41].…”

Section: Chemoradiotherapy: Preventionmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review of amifostine for the management of oral mucositis in cancer patients

Nicolatou‐Galitis

Sarri²,

Bowen

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

Purpose The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. Methods A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. Results Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. No guideline was possible for amifostine in any cancer treatment setting due to inadequate and conflicting evidence. Conclusion Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support its use in any cancer treatment

show abstract

Section: Subcutaneous Administrationmentioning

confidence: 99%

“…Four articles were reviewed [31,41,43,44]. The rate of oral mucositis was not improved with amifostine in one randomized but neither blinded nor placebo-controlled study [31].…”

Section: Chemoradiotherapy: Preventionmentioning

confidence: 99%

Section: Chemoradiotherapy: Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of amifostine for the management of oral mucositis in cancer patients

Nicolatou‐Galitis

Sarri²,

Bowen

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…In terms of late side effects, grade 3 xerostomia and grade 3 fibrosis occurred in 15% and 0% of the patients, respectively, but their study did not include a control group to compare the efficacy of amifostine. 34 Brizel et al reported the results of a multi-center, randomized phase III study on the efficacy of amifostine that included 315 patients. 35 Assessments were performed weekly before and during RT, and at certain intervals after RT.…”

Section: Discussionmentioning

confidence: 99%

“…44 In a study by Ozsahin et al, despite the fact that amifostine was interrupted due to nausea in 33% of patients and due to hypotension in 18%, it was well tolerated in nearly half of the patients. 34 Law et al noted that grade 1 nausea/ vomiting occurred in 35% of patients after subcutaneous administration. 18 Among the patients in the present study that received intravenous amifostine, 21.9%, 9.7%, and 4.8% had grade 1, 2, and 3 nausea, respectively, 2.4% had syncope, 9.7% had hypotension, and 2.4% had skin rash.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Amifostine on Acute and Late Radiation Side Effects in Head and Neck Cancer Patients

Demiroz¹,

Özkan²,

Cebelli³

et al. 2012

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

A AB BS ST TR RA AC CT T O Ob bj je ec ct ti iv ve e: : We aimed to investigate the effect of amifostine on acute and late side effects, and its tolerability in head and neck cancer patients treated with radiotherapy (RT). M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : The study included 87 patients with primary head and neck cancers and cervical lymph node metastases from unknown primary cancers treated with RT alone or combined with chemotherapy (CT). Forty-one patients (47%) received amifostine combined with RT (ART group) and 46 patients (52%) received RT without amifostine (RT group). The patients were evaluated every week during the treatment and at month 1 and 2 after the completion of RT for acute side effects and month 3, 6, 9, 12, and 24 after the treatment for late side effects according to SOMA/LENT scale. Amifostine was administered prior to RT, along with anti-emetic prophylaxis. The two groups were compared with the Student's t and MannWhitney U and Chi-square tests. R Re es su ul lt ts s: : The ART group had significantly less toxicity (grade 1 mucositis, grade 2 fibrosis) than patients in the RT group (p=0.001, p=0.03, respectively). At week 3 of RT grade 2 mucositis developed in two patients (5%) in the ART group and 10 patients (22%) in the RT group (p=0.02). The protective effect of amifostine on skin reactions developed at week 4 of RT (p=0.05). Grade 3 xerostomia at 9, 12, and 15 months of follow-up (p=0.02, p=0.02, and p=0.02, respectively), grade 2 xerostomia at 18 and 24 months (p=0.02 and p=0.01, respectively) and fibrosis at 15, 18 and 24 months (p=0.05, p=0.02 and p=0.02, respectively) decreased markedly in the ART group compared with the RT group. Emesis was the most common adverse effect of amifostine. C Co on nc cl lu us si io on n: : Daily administration of amifostine during RT was effective in avoiding late grade 2-3 xerostomia, as well as grade 2 fibrosis. K Ke ey y W Wo or rd ds s: : Radiotherapy; head and neck cancer; amifostine; xerostomia Ö ÖZ ZE ET T A Am ma aç ç: : Amifostinin radyoterapi (RT) ile tedavi edilmiş baş ve boyun kanseri hastalarında akut ve geç yan etkiler üzerindeki etkisini ve tolerabilitesini araştırmayı amaçladık. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Çalışmaya, tek başına RT veya RT ve eş zamanlı kemoterapi (KT) ile tedavi edilmiş primer baş ve boyun kanseri olan ve primeri bilinmeyen bir kanserden servikal lenf düğümlerine metastaz yapmış 87 hasta dâhil edildi. Kırk bir hastaya (47%) RT ile birlikte amifostin (ART grup) ve 46 hastaya (52%) amifostin olmaksızın RT (RT grubu) verildi. Olgular, tedavi sırasında akut yan etkiler açısından her hafta ve RT bittikten sonra 1. ve 2. ayda, geç yan etkiler açısından ise tedavi bittikten sonra 3., 6., 9., 12., ve 24. aylarda SOMA/LENT skalasına göre değerlendirildiler. Amifostin RT'den önce antiemetik profilaksi ile beraber uygulandı. İki grubun, komplikasyonlar üzerindeki etki açısından karşılaştırılmasında Student-t ve Mann Whitney-u testleri kullanıldı. B Bu ul lg gu ul la ar r: : AR...

show abstract

Established and Emerging Uses of Cytoprotection in Head and Neck Cancer

Rosenthal

2006

Arch Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Feasibility and Efficacy of Subcutaneous Amifostine Therapy in Patients With Head and Neck Cancer Treated With Curative Accelerated Concomitant-Boost Radiation Therapy

Abstract: To assess the feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated radiotherapy (RT).

Cited by 24 publications

References 36 publications

Systematic review of amifostine for the management of oral mucositis in cancer patients

Systematic review of amifostine for the management of oral mucositis in cancer patients

The Effect of Amifostine on Acute and Late Radiation Side Effects in Head and Neck Cancer Patients

Established and Emerging Uses of Cytoprotection in Head and Neck Cancer

Contact Info

Product

Resources

About